Maria Bekkenes1,2, Marte Morin Jørgensen3, Anne Flem Jacobsen2,4, Morten Wang Fagerland5, Helene Rakstad-Larsen4, Ole Geir Solberg6, Lars Aaberge6, Olav Klingenberg2,7, Trude Steinsvik8, Leiv Arne Rosseland1,2. 1. Department of Research and Development, Division of Emergencies and Critical Care, Oslo University Hospital, Oslo, Norway. 2. Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway. 3. Department of Anaesthesia, Akershus University Hospital, Lørenskog, Norway. 4. Division of Obstetrics and Gynaecology, Oslo University Hospital, Oslo, Norway. 5. Oslo Centre for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital, Oslo, Norway. 6. Department of Cardiology, Oslo University Hospital, Oslo, Norway. 7. Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway. 8. Department of Laboratory Medicine, Drammen Hospital, Vestre Viken Hospital Trust, Drammen, Norway.
Abstract
Background: Both oxytocin and carbetocin are used to prevent uterine atony and post-partum haemorrhage after caesarean delivery in many countries, including Norway. Oxytocin causes dose-dependent ST-depression, troponin release, prolongation of QT-time and arrythmia, but little is known about myocardial effects of carbetocin. We have previously demonstrated comparable vasodilatory effects of oxytocin and carbetocin and are now undertaking a Phase 4 trial to investigate whether carbetocin causes similar changes to myocardial markers compared with oxytocin. Methods: Our randomized controlled trial will be conducted at three obstetrics units at Oslo University Hospital and Akershus University Hospital, Norway. Planned enrolment will be of 240 healthy, singleton pregnant women aged 18 to 50 years undergoing planned caesarean delivery. Based on pilot study data, each participant will receive a one-minute intravenous injection of either oxytocin 2.5 IU or carbetocin 100 µg during caesarean delivery. The prespecified primary outcome is the change from baseline in high-sensitive troponin I plasma concentrations at 6-10 hours after study drug administration. Secondary outcomes include uterine tone grade at 2.5 and five minutes after study drug administration, adverse events for up to 48 hours after study drug administration, estimated blood loss within eight hours of delivery, need for rescue treatment and direct/indirect costs. Enrolment and primary analysis are expected to be completed by the end of 2021. Discussion: Women undergoing caesarean delivery should be assessed for cardiovascular risk particularly as women with an obstetric history of pregnancy induced hypertension, gestational diabetes mellitus, preterm birth, placental abruption, and stillbirth are at increased risk of future cardiovascular disease. Any additional ischaemic myocardial risk from uterotonic agents will need to be balanced with the benefit of reducing the risk of postpartum haemorrhage. Any potential cardiotoxicity difference between oxytocin and carbetocin will help inform treatment decisions for pregnant women. Registration: Clinicaltrials.gov NCT03899961 (02/04/2019). Copyright:
Background: Both oxytocin and carbetocin are used to prevent uterine atony and post-partum haemorrhage after caesarean delivery in many countries, including Norway. Oxytocin causes dose-dependent ST-depression, troponin release, prolongation of QT-time and arrythmia, but little is known about myocardial effects of carbetocin. We have previously demonstrated comparable vasodilatory effects of oxytocin and carbetocin and are now undertaking a Phase 4 trial to investigate whether carbetocin causes similar changes to myocardial markers compared with oxytocin. Methods: Our randomized controlled trial will be conducted at three obstetrics units at Oslo University Hospital and Akershus University Hospital, Norway. Planned enrolment will be of 240 healthy, singleton pregnant women aged 18 to 50 years undergoing planned caesarean delivery. Based on pilot study data, each participant will receive a one-minute intravenous injection of either oxytocin 2.5 IU or carbetocin 100 µg during caesarean delivery. The prespecified primary outcome is the change from baseline in high-sensitive troponin I plasma concentrations at 6-10 hours after study drug administration. Secondary outcomes include uterine tone grade at 2.5 and five minutes after study drug administration, adverse events for up to 48 hours after study drug administration, estimated blood loss within eight hours of delivery, need for rescue treatment and direct/indirect costs. Enrolment and primary analysis are expected to be completed by the end of 2021. Discussion: Women undergoing caesarean delivery should be assessed for cardiovascular risk particularly as women with an obstetric history of pregnancy induced hypertension, gestational diabetes mellitus, preterm birth, placental abruption, and stillbirth are at increased risk of future cardiovascular disease. Any additional ischaemic myocardial risk from uterotonic agents will need to be balanced with the benefit of reducing the risk of postpartum haemorrhage. Any potential cardiotoxicity difference between oxytocin and carbetocin will help inform treatment decisions for pregnant women. Registration: Clinicaltrials.gov NCT03899961 (02/04/2019). Copyright:
Authors: I Pisani; G M Tiralongo; G Gagliardi; R L Scala; C Todde; M G Frigo; H Valensise Journal: Pregnancy Hypertens Date: 2012-01-31 Impact factor: 2.899
Authors: Sonia M Grandi; Kristian B Filion; Sarah Yoon; Henok T Ayele; Carla M Doyle; Jennifer A Hutcheon; Graeme N Smith; Genevieve C Gore; Joel G Ray; Kara Nerenberg; Robert W Platt Journal: Circulation Date: 2019-02-19 Impact factor: 29.690
Authors: M Heesen; B Carvalho; J C A Carvalho; J J Duvekot; R A Dyer; D N Lucas; N McDonnell; S Orbach-Zinger; S M Kinsella Journal: Anaesthesia Date: 2019-07-25 Impact factor: 6.955
Authors: Ioannis D Gallos; Helen M Williams; Malcolm J Price; Abi Merriel; Harold Gee; David Lissauer; Vidhya Moorthy; Aurelio Tobias; Jonathan J Deeks; Mariana Widmer; Özge Tunçalp; Ahmet Metin Gülmezoglu; G Justus Hofmeyr; Arri Coomarasamy Journal: Cochrane Database Syst Rev Date: 2018-04-25
Authors: Tom E F Abbott; Rupert M Pearse; R Andrew Archbold; Tahania Ahmad; Edyta Niebrzegowska; Andrew Wragg; Reitze N Rodseth; Philip J Devereaux; Gareth L Ackland Journal: Anesth Analg Date: 2018-06 Impact factor: 5.108
Authors: Maria Bekkenes; Marte Morin Jørgensen; Anne Flem Jacobsen; Morten Wang Fagerland; Helene Rakstad-Larsen; Ole Geir Solberg; Lars Aaberge; Olav Klingenberg; Trude Steinsvik; Leiv Arne Rosseland Journal: F1000Res Date: 2021-09-27